Ubiquitin Proteasome Market

Global Ubiquitin Proteasome Market Size (2024 to 2029)

The size of the ubiquitin proteasome market is estimated to be worth USD 59.34 billion in 2024 and is anticipated to reach USD 72.54 billion by 2029, with a CAGR of 4.1% during the forecast period.

Current Scenario of Ubiquitin Proteasome Market

Currently, the ubiquitin proteasome market is in monopolistic competition and is gradually gaining traction. The rising number of cancer-related deaths is fueling the need for more developments in this domain. Moreover, the domain of targeted protein degradation (TPD) is relatively new. Consequently, production procedures for TPDs are still in their early stages and new technologies and approaches are being created to enhance effectiveness and affordability. Further, experts are actively engaged in making new tactics to solve problems and restrictions and lead the way for greater efficiency and particular TPD therapies.

MARKET DRIVERS

The ubiquitin proteasome market is driven by the growing number of patients diagnosed with cancer. This system is highly crucial for cellular homeostasis and cancer progression. Its capability to manage the constancy of proteins that cause cancer to rise and survive demonstrates its ability as a therapeutic target. Within UPS elements, ubiquitin-conjugating enzymes, like ubiquitin-conjugating enzyme E2 J1 (UBE2J1), have grown as the main performers in cancer dynamics, particularly in prostate cancer (PCa) where treatment resistance is a key issue. For instance, in June 2024, it was published that experts from the University of Southwestern Medical Center in its latest research found the role of UBE2J1 in PCa, especially its engagement in the destruction of the androgen receptor (AR). For this, it used an extensive screening of the vivo library.

The market is also benefiting from greater efforts in research projects and subsequent discoveries for more precise cancer drugs with minimal side effects. Like, the development of inhibitors of the enzyme USP28 forming the base of several anti-cancer drugs currently in progress, breaks up cell division by obstructing this enzyme.

Additionally, the market expansion is also supported by the availability and generation of healthcare data. The application of big data in the healthcare industry has considerably boosted its ability to conduct research and development projects and better understand functions and others.

The targeted protein degradation (TPD) for drug discovery provides new avenues for the ubiquitin proteasome market. It quickly gained attention as a therapeutic modality because of the different benefits offered involving fewer side effects, stability and specificity. Also, it presents a huge potential for market expansion in immunobiology, cancer biology and chemical biology. Apart from this, it is significant that these destructors provide wide usage and can attain exclusiveness for their protein goals by improving the connector length and fixing the ternary complexes.

Additionally, the advancement of protein-based PROTACs has shown stimulating prospects for aiming for a broader variety of proteins, consisting of highly disordered, secreted and membrane proteins. Furthermore, an extensive range of E3 ligases has been engaged, offering greater flexibility against those of small molecule degraders. The achievements in the previous two decades and recent breakthroughs in both academic circles and industry indicated that TPD can be a major modality for improving therapeutics.

MARKET RESTRAINTS

The costly nature of drug development and stringent laws are restricting the growth of the ubiquitin proteasome market growth. Moreover, despite advancements in therapy and medicines, its side effects persist which is stopping it from achieving optimum results.

Besides this, targeted protein degradation (TPD) technologies have sought to transform the disciplines of chemical biology and biomedicine by offering unique study opportunities and potential therapeutics. However, they mainly emphasize the usage of small molecules to enrol the ubiquitin-proteasome system to intervene in target protein degradation. Also, traditional therapies or treatments like monoclonal antibodies and small molecules are good at obstructing protein function with occupancy-driven strategies. Consequently, this confines protein objectives such as non-enzymatic proteins, scaffolding proteins and transcription factors that lack suitable binding pockets.

The development of the Midnolin-Proteasome Pathway challenges the ubiquitin proteasome market growth. It is a newly discovered and innovative process for proteasomal reduction which is not dependent on ubiquitination. Moreover, this mednolin encourages the degradation of several nuclear proteins, involving transcription factors. For instance, in August 2023, investigators determined a vital protein known as midnolin which degrades short-term nuclear proteins. It is extremely important for gene expression and modulation, impacting brain development, immune responses and learning. This breakthrough answered long-standing, at least decades, questions concerning a ubiquitin-independent process for protein degradation.

REPORT COVERAGE

SEGMENTAL ANALYSIS

Global Ubiquitin Proteasome Market Analysis By Application

The cancer subsegment is expected to account for the biggest market share of ubiquitin proteasome during the forecast period. This can be attributed to its high prevalence and death rate worldwide, According to the Pan American Health Organization, there were an anticipated 20 million new cancer cases and about 10 million deaths from this globally. Also, its burden will surge by around 60 per cent in the next 20 years which will put significant pressure on healthcare systems and societies, hence the subsegment’s market size is predicted to elevate in the future. Moreover, the latest scientific discoveries give a vital base for the hunt for more particular drugs with reduced side effects. Thus, influencing the growth of the ubiquitin proteasome market.

Global Ubiquitin Proteasome Market Analysis By Product Type

The small molecule inhibitors segment is spearheading the category and is currently experiencing higher traction in the ubiquitin proteasome market. The rising frequency of neurodegenerative and cancer diseases propels the need for this. In addition, renowned establishments and Universities have strongly emphasized R&D operations in the domain of ubiquitin-proteasome inhibitors. Furthermore, the demand for science equipment and reagents for high-output screening trials is surging, as investigators look to determine and confirm new drug candidates which can regulate the UPS efficiently. Whereas, the biologics segment is rapidly advancing, especially with the development of monoclonal antibodies and other big molecules.

Global Ubiquitin Proteasome Market Analysis By End-User

The pharmaceutical companies segment has been the major contributor to the expansion of the ubiquitin proteasome market in recent years. They invested substantial amounts in R&D to address the challenges faced in the traditional process of discovering new drugs and therapies. Apart from this, the popularity of existing drugs such as bortezomib (Velcade) and carfilzomib (Kyprolis) has established a robust industrial interest in this field. Moreover, the ongoing progress on novel compounds involving PROTACs and small-molecule inhibitors shows the dynamic nature of this segment.

On the other hand, the biotechnology firms segment is quickly emerging as a key player in the ubiquitin proteasome industry and is expected to capture a notable market share. The segment grew tremendously due to increased collaboration with pharma players. Arvinas, C4 Therapeutics, Fluidic Analytics, NEOsphere Biotechnologies, Origami Therapeutics and Ranok Therapeutics are a few key companies in the market.

Regional Analysis

North America leads the ubiquitin proteasome market. The regional market is driven by the United States has experienced a substantial growth in the number of cancer patients. According to the American Cancer Society, in 2022, there will be about 1958310 new cancer cases and about 609820 deaths from cancer including teenagers and young people aged between 15 to 39 years in the US. Also, Prostate and breast cancers are the widely common types of cancer in the area. Likewise, as per the National Institute of Health, about 1.2 million individuals in the United States are expected to suffer from Parkinson’s disease by 2030. It is the second-most prevalent neurodegenerative condition in the country. Besides this, thousands of possible cases go unidentified. As the elderly population numbers continue to rise, the volume of patients suffering from Parkinson's disease (PD) will continue to rise and this is estimated to become two fold by 2040.

Key Market Players

Tocris Bioscience, Merck KGaA, BioVision Inc., Takeda Pharmaceuticals, and Promega Corporation are some of the key market players in the ubiquitin proteasome market.

Recent Market Developments

• In June 2024, the European Research Council (ERC) announced the awarding of an advanced grant of 2.5 million euros to Professor Helle Ulrich to aid her study on how ubiquitin helps in DNA repair and the sustenance of genome stability.

• In January 2024, researchers and experts from the Nano Life Science Institute (WPI-NanoLSI) at Kanazawa University reported the outcome of its study of the flexibility of a protein hinge while transferring proteins in cells. It concluded that ubiquitination is caused by the reorganization of protein around this hinge. Moreover, this hinge of the enzyme can bend and change location.

• In August 2023, investigators determined a vital protein known as midnolin which degrades short-term nuclear proteins. It is extremely important for gene expression, impacting brain development, immune responses and learning. This breakthrough answered long-standing, at least decades, questions concerning a ubiquitin-independent process for protein degradation.

DETAILED SEGMENTATION OF THE GLOBAL UBIQUITIN PROTEASOME MARKET INCLUDED IN THIS REPORT

This research report on the global ubiquitin proteasome market has been segmented and sub-segmented based on the following categories.

By Application

• Scientific Research

• Treatment

• Cancer

• Neurodegenerative Disease

• Others

By Product Type

• Small Molecule Inhibitors

• Biologics

• Diagnostics

By End-User

• Pharmaceutical Companies

• Academic Institutions

• Biotechnology firms

By Region

• North America

• Europe

• Asia Pacific

• Latin America

• Middle East and Africa